Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

Next Previous
Trial Profile

Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BA 015 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Valerio Therapeutics

Most Recent Events

  • 07 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
  • 07 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 01 Oct 2012 Results were reported at the 37th Congress of the European Society of Medical Oncology (ESMO-2012), according to a BioAlliance Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top